# Table 34 generation works with default values

    Code
      res
    Output
      Body System or Organ Class                                            
        FMQ (Narrow)                A: Drug X    B: Placebo   C: Combination
          Dictionary-Derived Term    (N=134)      (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————
      cl A.1                                                                
        FMQ1                        17 (12.7%)   14 (10.4%)     29 (22.0%)  
          dcd A.1.1.1.1              7 (5.2%)     6 (4.5%)      13 (9.8%)   
          dcd A.1.1.1.2             12 (9.0%)     8 (6.0%)      18 (13.6%)  
        FMQ2                        23 (17.2%)   20 (14.9%)     20 (15.2%)  
          dcd A.1.1.1.1             13 (9.7%)    10 (7.5%)      12 (9.1%)   
          dcd A.1.1.1.2             12 (9.0%)    10 (7.5%)       8 (6.1%)   
        FMQ3                        20 (14.9%)   19 (14.2%)     23 (17.4%)  
          dcd A.1.1.1.1              8 (6.0%)     8 (6.0%)      13 (9.8%)   
          dcd A.1.1.1.2             13 (9.7%)    11 (8.2%)      11 (8.3%)   
      cl B.1                                                                
        FMQ1                         8 (6.0%)    11 (8.2%)       7 (5.3%)   
          dcd B.1.1.1.1              8 (6.0%)    11 (8.2%)       7 (5.3%)   
        FMQ2                         5 (3.7%)    12 (9.0%)      16 (12.1%)  
          dcd B.1.1.1.1              5 (3.7%)    12 (9.0%)      16 (12.1%)  
        FMQ3                        10 (7.5%)     7 (5.2%)       5 (3.8%)   
          dcd B.1.1.1.1             10 (7.5%)     7 (5.2%)       5 (3.8%)   
      cl B.2                                                                
        FMQ1                        13 (9.7%)    15 (11.2%)      9 (6.8%)   
          dcd B.2.1.2.1             13 (9.7%)    15 (11.2%)      9 (6.8%)   
        FMQ2                        12 (9.0%)     9 (6.7%)      10 (7.6%)   
          dcd B.2.1.2.1             12 (9.0%)     9 (6.7%)      10 (7.6%)   
        FMQ3                         6 (4.5%)     7 (5.2%)       9 (6.8%)   
          dcd B.2.1.2.1              6 (4.5%)     7 (5.2%)       9 (6.8%)   
      cl C.2                                                                
        FMQ1                         9 (6.7%)     9 (6.7%)      12 (9.1%)   
          dcd C.2.1.2.1              9 (6.7%)     9 (6.7%)      12 (9.1%)   
        FMQ2                         6 (4.5%)     8 (6.0%)       8 (6.1%)   
          dcd C.2.1.2.1              6 (4.5%)     8 (6.0%)       8 (6.1%)   
        FMQ3                         6 (4.5%)     9 (6.7%)      10 (7.6%)   
          dcd C.2.1.2.1              6 (4.5%)     9 (6.7%)      10 (7.6%)   
      cl D.1                                                                
        FMQ1                        23 (17.2%)   17 (12.7%)     27 (20.5%)  
          dcd D.1.1.1.1              9 (6.7%)     9 (6.7%)      12 (9.1%)   
          dcd D.1.1.4.2             14 (10.4%)   10 (7.5%)      16 (12.1%)  
        FMQ2                        22 (16.4%)   20 (14.9%)     25 (18.9%)  
          dcd D.1.1.1.1             15 (11.2%)   10 (7.5%)      16 (12.1%)  
          dcd D.1.1.4.2             10 (7.5%)    10 (7.5%)      10 (7.6%)   
        FMQ3                        15 (11.2%)   19 (14.2%)     21 (15.9%)  
          dcd D.1.1.1.1              9 (6.7%)    10 (7.5%)      12 (9.1%)   
          dcd D.1.1.4.2              6 (4.5%)    11 (8.2%)       9 (6.8%)   
      cl D.2                                                                
        FMQ1                         8 (6.0%)    11 (8.2%)       9 (6.8%)   
          dcd D.2.1.5.3              8 (6.0%)    11 (8.2%)       9 (6.8%)   
        FMQ2                        14 (10.4%)   15 (11.2%)     14 (10.6%)  
          dcd D.2.1.5.3             14 (10.4%)   15 (11.2%)     14 (10.6%)  
        FMQ3                        11 (8.2%)     9 (6.7%)      11 (8.3%)   
          dcd D.2.1.5.3             11 (8.2%)     9 (6.7%)      11 (8.3%)   

# Table 34 generation works with custom values

    Code
      res
    Output
      Table 34. Patients With Serious Adverse Events(1) by System Organ Class, FDA Medical Query (Broad) and Preferred Term, Safety Population, Pooled Analyses or Trial X(2)
      
      ——————————————————————————————————————————————————————————————————————————
      Body System or Organ Class(3)(4)                                          
        FMQ (Broad)                      A: Drug X   B: Placebo   C: Combination
          Dictionary-Derived Term         (N=134)     (N=134)        (N=132)    
      ——————————————————————————————————————————————————————————————————————————
      cl B.2                                                                    
        FMQ1                             8 (6.0%)    10 (7.5%)       8 (6.1%)   
          dcd B.2.2.3.1                  8 (6.0%)    10 (7.5%)       8 (6.1%)   
        FMQ2                             12 (9.0%)   12 (9.0%)      13 (9.8%)   
          dcd B.2.2.3.1                  12 (9.0%)   12 (9.0%)      13 (9.8%)   
        FMQ3                             8 (6.0%)    16 (11.9%)      6 (4.5%)   
          dcd B.2.2.3.1                  8 (6.0%)    16 (11.9%)      6 (4.5%)   
      cl C.1                                                                    
        FMQ1                             7 (5.2%)    11 (8.2%)      14 (10.6%)  
          dcd C.1.1.1.3                  7 (5.2%)    11 (8.2%)      14 (10.6%)  
        FMQ2                             10 (7.5%)   16 (11.9%)      7 (5.3%)   
          dcd C.1.1.1.3                  10 (7.5%)   16 (11.9%)      7 (5.3%)   
        FMQ3                             8 (6.0%)     5 (3.7%)      12 (9.1%)   
          dcd C.1.1.1.3                  8 (6.0%)     5 (3.7%)      12 (9.1%)   
      ——————————————————————————————————————————————————————————————————————————
      
      Source: [include Applicant source, datasets and/or software tools used
       (1) Defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires hospitalization or prolongation of existing
       hospitalization, results in persistent incapacity or substantial disruption of the ability to conduct normal life functions, or is a congenital anomaly, or birth defect.
       (2) Duration = [e.g., X-week double-blind treatment period or, median and a range indicating pooled trial durations].
       (3) Treatment-emergent adverse event defined as [definition].
       (4) Each FMQ is aligned to a single SOC based on clinical judgement. However, please be aware that some FMQs may contain PTs from more than one SOC.
      
      Abbreviations: CI, confidence interval; FMQ, FDA Medical Query; N, number of patients in treatment arm;
      n, number of patients with at least one event; SOC, System Organ Class

# Table 34 generation works with risk difference column

    Code
      res
    Output
      Body System or Organ Class                                                                           
        FMQ (Narrow)                A: Drug X    B: Placebo   C: Combination   Risk Difference (%) (95% CI)
          Dictionary-Derived Term    (N=134)      (N=134)        (N=132)                 (N=268)           
      —————————————————————————————————————————————————————————————————————————————————————————————————————
      cl A.1                                                                                               
        FMQ1                        17 (12.7%)   14 (10.4%)     29 (22.0%)          -2.2 (-9.9 - 5.4)      
          dcd A.1.1.1.1              7 (5.2%)     6 (4.5%)      13 (9.8%)           -0.7 (-5.9 - 4.4)      
          dcd A.1.1.1.2             12 (9.0%)     8 (6.0%)      18 (13.6%)          -3.0 (-9.3 - 3.3)      
        FMQ2                        23 (17.2%)   20 (14.9%)     20 (15.2%)          -2.2 (-11.0 - 6.5)     
          dcd A.1.1.1.1             13 (9.7%)    10 (7.5%)      12 (9.1%)           -2.2 (-8.9 - 4.5)      
          dcd A.1.1.1.2             12 (9.0%)    10 (7.5%)       8 (6.1%)           -1.5 (-8.1 - 5.1)      
        FMQ3                        20 (14.9%)   19 (14.2%)     23 (17.4%)          -0.7 (-9.2 - 7.7)      
          dcd A.1.1.1.1              8 (6.0%)     8 (6.0%)      13 (9.8%)            0.0 (-5.7 - 5.7)      
          dcd A.1.1.1.2             13 (9.7%)    11 (8.2%)      11 (8.3%)           -1.5 (-8.3 - 5.3)      
      cl B.1                                                                                               
        FMQ1                         8 (6.0%)    11 (8.2%)       7 (5.3%)            2.2 (-3.9 - 8.4)      
          dcd B.1.1.1.1              8 (6.0%)    11 (8.2%)       7 (5.3%)            2.2 (-3.9 - 8.4)      
        FMQ2                         5 (3.7%)    12 (9.0%)      16 (12.1%)          5.2 (-0.6 - 11.0)      
          dcd B.1.1.1.1              5 (3.7%)    12 (9.0%)      16 (12.1%)          5.2 (-0.6 - 11.0)      
        FMQ3                        10 (7.5%)     7 (5.2%)       5 (3.8%)           -2.2 (-8.1 - 3.6)      
          dcd B.1.1.1.1             10 (7.5%)     7 (5.2%)       5 (3.8%)           -2.2 (-8.1 - 3.6)      
      cl B.2                                                                                               
        FMQ1                        13 (9.7%)    15 (11.2%)      9 (6.8%)            1.5 (-5.8 - 8.8)      
          dcd B.2.1.2.1             13 (9.7%)    15 (11.2%)      9 (6.8%)            1.5 (-5.8 - 8.8)      
        FMQ2                        12 (9.0%)     9 (6.7%)      10 (7.6%)           -2.2 (-8.7 - 4.2)      
          dcd B.2.1.2.1             12 (9.0%)     9 (6.7%)      10 (7.6%)           -2.2 (-8.7 - 4.2)      
        FMQ3                         6 (4.5%)     7 (5.2%)       9 (6.8%)            0.7 (-4.4 - 5.9)      
          dcd B.2.1.2.1              6 (4.5%)     7 (5.2%)       9 (6.8%)            0.7 (-4.4 - 5.9)      
      cl C.2                                                                                               
        FMQ1                         9 (6.7%)     9 (6.7%)      12 (9.1%)            0.0 (-6.0 - 6.0)      
          dcd C.2.1.2.1              9 (6.7%)     9 (6.7%)      12 (9.1%)            0.0 (-6.0 - 6.0)      
        FMQ2                         6 (4.5%)     8 (6.0%)       8 (6.1%)            1.5 (-3.8 - 6.8)      
          dcd C.2.1.2.1              6 (4.5%)     8 (6.0%)       8 (6.1%)            1.5 (-3.8 - 6.8)      
        FMQ3                         6 (4.5%)     9 (6.7%)      10 (7.6%)            2.2 (-3.3 - 7.7)      
          dcd C.2.1.2.1              6 (4.5%)     9 (6.7%)      10 (7.6%)            2.2 (-3.3 - 7.7)      
      cl D.1                                                                                               
        FMQ1                        23 (17.2%)   17 (12.7%)     27 (20.5%)          -4.5 (-13.0 - 4.0)     
          dcd D.1.1.1.1              9 (6.7%)     9 (6.7%)      12 (9.1%)            0.0 (-6.0 - 6.0)      
          dcd D.1.1.4.2             14 (10.4%)   10 (7.5%)      16 (12.1%)          -3.0 (-9.8 - 3.8)      
        FMQ2                        22 (16.4%)   20 (14.9%)     25 (18.9%)          -1.5 (-10.2 - 7.2)     
          dcd D.1.1.1.1             15 (11.2%)   10 (7.5%)      16 (12.1%)          -3.7 (-10.7 - 3.2)     
          dcd D.1.1.4.2             10 (7.5%)    10 (7.5%)      10 (7.6%)            0.0 (-6.3 - 6.3)      
        FMQ3                        15 (11.2%)   19 (14.2%)     21 (15.9%)          3.0 (-5.0 - 10.9)      
          dcd D.1.1.1.1              9 (6.7%)    10 (7.5%)      12 (9.1%)            0.7 (-5.4 - 6.9)      
          dcd D.1.1.4.2              6 (4.5%)    11 (8.2%)       9 (6.8%)            3.7 (-2.1 - 9.6)      
      cl D.2                                                                                               
        FMQ1                         8 (6.0%)    11 (8.2%)       9 (6.8%)            2.2 (-3.9 - 8.4)      
          dcd D.2.1.5.3              8 (6.0%)    11 (8.2%)       9 (6.8%)            2.2 (-3.9 - 8.4)      
        FMQ2                        14 (10.4%)   15 (11.2%)     14 (10.6%)           0.7 (-6.7 - 8.2)      
          dcd D.2.1.5.3             14 (10.4%)   15 (11.2%)     14 (10.6%)           0.7 (-6.7 - 8.2)      
        FMQ3                        11 (8.2%)     9 (6.7%)      11 (8.3%)           -1.5 (-7.8 - 4.8)      
          dcd D.2.1.5.3             11 (8.2%)     9 (6.7%)      11 (8.3%)           -1.5 (-7.8 - 4.8)      

